I see this arrangement as business opportunities for both sides:
Altium takes the current down turn in the stock market as opportunity, for their cheap exposure in Lag3 immutgerapy science at an advanced clinical development stage.
Management used the opportunity to gain a specialist US institutional support in the US equity market.
I see this arrangement as business opportunities for both...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.020(6.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $913.3K | 3.099M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 124895 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 30287 | 2 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
